TP53 and B-cell chronic lymphocytic leukemia: The European Research Initiative on CLL (ERIC) has generated guidelines for the analysis of both TP53 and IGHV mutational status and provides the possibility of an accreditation process that is being offered worldwide to centers [42,43].